| 1 |
23558838 | Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. | 2013 May |
1 |
| 2 |
20978128 | Basal bioenergetic abnormalities in skeletal muscle from ryanodine receptor malignant hyperthermia-susceptible R163C knock-in mice. | 2011 Jan 7 |
1 |
| 3 |
20023768 | Impaired interaction between skeletal ryanodine receptors in malignant hyperthermia. | 2009 Sep |
5 |
| 4 |
18505726 | Reduced threshold for luminal Ca2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia. | 2008 Jul 25 |
1 |
| 5 |
12959958 | Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle. | 2004 Jan |
2 |
| 6 |
15269663 | [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex]. | 2004 May |
1 |
| 7 |
14641996 | Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala. | 2003 Fall |
2 |
| 8 |
12124989 | RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. | 2002 Aug |
1 |
| 9 |
12151923 | Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations. | 2002 Aug |
2 |
| 10 |
12393358 | Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells. | 2002 Oct |
1 |
| 11 |
9873004 | Measurement of resting cytosolic Ca2+ concentrations and Ca2+ store size in HEK-293 cells transfected with malignant hyperthermia or central core disease mutant Ca2+ release channels. | 1999 Jan 8 |
1 |
| 12 |
10097181 | A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. | 1999 Mar 30 |
2 |
| 13 |
9743407 | Treatment of normal skeletal muscle with FK506 or rapamycin results in halothane-induced muscle contracture. | 1998 Sep |
1 |